PPIDT00417
Drug Information
| Name | Tafasitamab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15044 |
| Type | biotech |
| Indication | Tafasitamab is indicated, in combination with [lenalidomide], for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified whom are ineligible for autologous stem cell transplant (ASCT).[L15292] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous |
200 MG
|
| Powder, for solution | Intravenous |
200 mg / vial
|
| Injection, powder, lyophilized, for solution | Intravenous |
200 mg/5mL
|